Company intelligence / Profile preview

OSRX, Inc.

Missoula, Montana, United States

Ownership: Private
Employees: ~31
Development stage: Other

Overview

OSRX is an FDA-registered 503B outsourcing facility and PCAB-accredited compounding pharmacy specializing in customized ophthalmic medications. The company formulates 14 customized ophthalmic medications and offers products through its OMNI and EyeFocus® portfolios for surgical vision correction, myopia control, and glaucoma management. As of August 2024, OSRX achieved 503B outsourcing facility status, allowing bulk manufacturing to medical facilities in addition to patient-specific prescriptions. However, in April 2025, the FDA issued a warning letter indicating serious deficiencies in sterile drug production practices.

Therapeutic areas: Ophthalmology
Modalities: Small moleculeCompounded ophthalmic solution
Industry: Biotech

Partnerships

Luis Felipe Vejarano, MD (EyeFocus licensing and development partnership)

Beyond the preview

Go deeper on OSRX, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OSRX, Inc..

Explore the full profile